Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04071366 · ClinicalTrials.gov registry record · Phase 2
A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT04071366 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 112 participants.
The verdict
NCT04071366, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
"The purpose of this study is to assess the safety and efficacy of oral administration of itacitinib for the prevention of cytokine release syndrome (CRS) in male or female participants aged 12 years or older and who are planning to receive an approved immune effector cell (IEC) therapy for hematologic malignancies.
Interventions
- DRUG Placebo
- DRUG Itacitinib
- DRUG Immune effector cell therapy
- BIOLOGICAL Yescarta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2020-02-07 |
| Est. Completion | 2023-08-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04071366
The ClinicalTrials.gov registry entry for NCT04071366 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04071366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04071366 about?
NCT04071366 is a clinical study titled "A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy". "The purpose of this study is to assess the safety and efficacy of oral administration of itacitinib for the prevention of cytokine release syndrome (CRS) in male or female participants aged 12 years or older and who are planning to receive an approved immune effector cell (IEC) therapy for hematolo...
What is the current status of trial NCT04071366?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2020-02-07. Estimated completion is 2023-08-22.
What interventions are being tested in trial NCT04071366?
The interventions under investigation include: Placebo (DRUG), Itacitinib (DRUG), Immune effector cell therapy (DRUG), Yescarta (BIOLOGICAL).
Who is sponsoring clinical trial NCT04071366?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.